IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival

The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this i... Author: VJOncology Added: 04/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts